Monique Giguère, Ph.D. - Programs Director
Mont-Saint-Hilaire, Quebec, J3H 6C4, Canada
NCT Number: NCT00112177
Itopride is a new compound that is already marketed in Japan and in some countries of Eastern Europe under the name of Ganaton. It is used to treat symptoms of functional dyspepsia. Patients suffering from this condition have difficulties digesting food. They feel full after eating a few bites; they feel bloated and their stomachs hurt. The goal of this study is to see if itopride helps to relieve the symptoms of functional dyspepsia.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 3
Mont-Saint-Hilaire, Quebec, J3H 6C4, Canada
The study lasts approximately 10 weeks. Patients may either receive the real itopride, or a sugar pill called placebo. They have equal chances of receiving either treatment. After having completed this study, patients may be eligible to continue treatment for a longer period. At that point, all patients receive itopride.
Patients need to come to the clinic for evaluations 4 times during the trial. Various evaluations are done at these visits, such as a physical exam, lab tests, evaluation of the heart condition, and questionnaires need to be completed by the patient to see if the drug helps them in relieving their symptoms.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Forest Laboratories
Industry
A Multicentre, Randomized, Double-Blind Placebo-Controlled Study of the Efficacy and Safety of Itopride HCl in Patients Suffering From Functional Dyspepsia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05810168
Digestive System Diseases, Dyspepsia
Sheffield, South Yorkshire, United Kingdom
View Trial DetailsNCT05004012
Digestive System Diseases, Dyspepsia
Los Angeles, California, United States
View Trial DetailsNCT06760897
Dysbiosis, Dyspepsia
Guangzhou, Guangdong, China
View Trial DetailsNCT06150638
Colonic Diseases, Colonic Diseases, Functional
Barcelona, Spain
View Trial Details